

CHAPTER VI

REFERENCES

- Adachi, Y., Ishiguro, J., Kotani, H., Hisada, T., Ichikawa, M., Gondo, N., Yoshimura, A., Kondo, N., Hattori, M., Sawaki, M., Fujita, T., Kikumori, T., Yatabe, Y., Kodera, Y. and Iwata, H. (2016). Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. *BMC Cancer*, 16(1).
- Agarwal, G. and Ramakant, P. (2008). Breast Cancer Care in India: The Current Scenario and the Challenges for the Future. *Breast Care*, 3(1), pp.21–27.
- Aiuti, A., Webb, I., Bleul, C., Springer, T. and Gutierrez-Ramos, J. (1997). The Chemokine SDF-1 Is a Chemoattractant for Human CD34+Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+Progenitors to Peripheral Blood. *The Journal of Experimental Medicine*, 185(1), pp.111-120.
- Allinen, M., Beroukhi, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., Schnitt, S., Sellers, W. and Polyak, k. (2004). Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell*, 6(1), pp.17-32.
- Appleton, D., Hackney, L. and Narayanan, S. (2014). Ultrasonography alone for diagnosis of breast cancer in women under 40. *Annals of The Royal College of Surgeons of England*, 96(3), pp.202-206.
- Ayoade, B., Agboola, A., Olatunji, A., Tade, A., Salami, B. and Adekoya, A. (2014). Clinical characteristics and survival outcome of breast cancer in southwest Nigerian women. *Journal Africain du Cancer / African Journal of Cancer*, 6(2), pp.79-84.
- Ayoade, B., Tade, A. and Salami, B. (2012). Clinical Features and Pattern of Presentation of Breast Diseases in Surgical Outpatient Clinic of a Suburban Tertiary Hospital in South-West Nigeria. *Nigerian Journal of Surgery: Official Publication of the Nigerian Surgical Research Society*, 18(1), pp.13-16.
- Balkwill, F. (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. *Seminars in Cancer Biology*, 14(3), pp.171-179.
- Bleul, C., Fuhlbrigge, R., Casasnovas, J., Aiuti, A. and Springer, T. (1996). A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *Journal of Experimental Medicine*, 184(3), pp.1101-1109.
- Bolger, N., Foster, M., Vinokur, A. and Ng, R. (1996). Close relationships and adjustments to a life crisis: The case of breast cancer. *Journal of Personality and Social Psychology*, 70(2), pp.283-294.
- Borish, L. and Steinke, J. (2003). 2. Cytokines and chemokines. *Journal of*

- Allergy and Clinical Immunology*, 111(2), pp.S460-S475.
- Breast cancer facts & figures 2015-2016. (2015). *American Cancer Society*, p.1.
- Brierley, J. (2006). The evolving TNM cancer staging system: an essential component of cancer care. *Canadian Medical Association Journal*, 174(2), pp.155-156.
- Busillo, J. and Benovic, J. (2007). Regulation of CXCR4 signaling. *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 1768(4), pp.952-963.
- Cabioglu, N., Sahin, A., Doucet, M., Yavuz, E., Igci, A., O.Yildirim, E., Aktas, E., Bilgic, S., Kiran, B., Deniz, G. and Price, J. (2005). Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. *Clinical & Experimental Metastasis*, 22(1), pp.39-46.
- Cabioglu, N., Sahin, A., Morandi, P., Meric-Bernstam, F., Islam, R., Lin, H., Bucana, C., Gonzalez-Angulo, A., Hortobagyi, G. and Cristofanilli, M. (2009). Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. *Annals of Oncology*, 20(6), pp.1013-1019.
- Chakraborty, S. and Rahman, T. (2012). The difficulties in cancer treatment. *ecancermedicalsecience*, 6(16).
- Chang, A. (2008). Breast Cancer in the Asia-Pacific Region. *Asia-Pacific Journal of Clinical Oncology*, 4, pp.S3-S4.
- Chen, M., Sun, H., Zhao, Y., Fu, W., Yang, L., Gao, S. and Jin, W. (2017). Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. *Scientific Reports*, 7, p.9254.
- Chu, Q., Panu, L., Holm, N., Li, B., Johnson, L. and Zhang, S. (2010). High Chemokine Receptor CXCR4 Level in Triple Negative Breast Cancer Specimens Predicts Poor Clinical Outcome. *Journal of Surgical Research*, 159(2), pp.689-695.
- Colzani, E., Johansson, A., Liljegren, A., Foukakis, T., Clements, M., Adolfsson, J., Hall, P. and Czene, K. (2014). Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. *British Journal of Cancer*, 110(5), pp.1378-1384.
- Corbex, M., Bouzbid, S. and Boffetta, P. (2014). Features of breast cancer in developing countries, examples from North-Africa. *European Journal of Cancer*, 50(10), pp.1808-1818.
- Cox, T. and Erler, J. (2011). Remodelling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Dis Model Mech*, 4(2), pp.165-178.
- Danny, R., Susanna, M., Cheng, H. and Peter, D. (2014). Incidence and mortality

- of female breast cancer in the Asia-Pacific region. *Cancer Biology & Medicine*, [online] 11(2), p.101.
- Dent, R., Hanna, W., Trudeau, M., Rawlinson, E., Sun, P. and Narod, S. (2008). Pattern of metastatic spread in triple-negative breast cancer. *Breast Cancer Research and Treatment*, 115(2), pp.423-428.
- Duda, D., Kozin, S., Kirkpatrick, N., Xu, L., Fukumura, D. and Jain, R. (2011). CXCL12 (SDF1)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?. *Clinical Cancer Research*, 17(8), pp.2074-2080.
- Eheman, C., Shaw, K., Ryerson, A., Miller, J., Ajani, U. and White, M. (2009). The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. *Cancer Epidemiology Biomarkers & Prevention*, 18(6), pp.1763-1769.
- Eisemann, N., Waldmann, A. and Katalinic, A. (2013). Epidemiology of Breast Cancer - Current Figures and Trends. *Geburtshilfe und Frauenheilkunde*, 73(02), pp.130-135.
- Ellis, I. (2005). Pathology Reporting of Breast Disease: A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. 1st ed. *Sheffield: NHS Cancer Screening Programmes*.
- Elston, C. and Ellis, I. (1991). pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology*, 19(5), pp.403-410.
- Ernst, M., van de Poll-Franse, L., Roukema, J., Coebergh, J., van Gestel, C., Vreugdenhil, G., Louwman, M. and Voogd, A. (2007). Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. *The Breast*, 16(4), pp.344-351.
- Erol, V., Icoz, G., Kose, T., Makay, O., Ertan, Y., Yazarbas, U., Akyildiz, M. and Yilmaz, M. (2013). The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer. *Turkish Journal of Surgery*.
- Fan, L., Strasser-Weippl, K., Li, J., St Louis, J., Finkelstein, D., Yu, K., Chen, W., Shao, Z. and Goss, P. (2014). Breast cancer in China. *The Lancet Oncology*, 15(7), pp.e279-e289.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D. and Bray, F. (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5), pp.E359-E386.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D., Forman, D. and Bray, F. (2013). GLOBOCAN 2012: Cancer

- Incidence and Mortality Worldwide. *International Agency for Research on Cancer*. 1(11).
- Freedman, D., Petitti, D. and Robins, J. (2004). On the efficacy of screening for breast cancer. *International Journal of Epidemiology*, 33(1), pp.43-55.
- Frkovic-Grazio, S. and Bracko, M. (2002). Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. *Journal of Clinical Pathology*, 55(2), pp.88-92.
- Galea, M., Blamey, R., Elston, C. and Ellis, I. (1992). The Nottingham prognostic index in primary breast cancer. *Breast Cancer Research and Treatment*, 22(3), pp.207-219.
- Goldhirsch, A., Ingle, J., Gelber, R., Coates, A., Thurlimann, B. and Senn, H. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. *Annals of Oncology*, 20(8), pp.1319-1329.
- Goldhirsch, A., Wood, W., Coates, A., Gelber, R., Thurlimann, B. and Senn, H. (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Annals of Oncology*, 22(8), pp.1736-1747.
- Giuliano, A., Connolly, J., Edge, S., Mittendorf, E., Rugo, H., Solin, L., Weaver, D., Winchester, D. and Hortobagyi, G. (2017). Breast Cancer-Major Changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA: A Cancer Journal for Clinicians*, 67(4), pp.290-303.
- Hamaoka, T. (2004). Bone Imaging in Metastatic Breast Cancer. *Journal of Clinical Oncology*, 22(14), pp.2942-2953.
- Hiller, D. and Chu, Q. (2011). CXCR4 and Axillary Lymph Nodes: Review of a Potential Biomarker for Breast Cancer Metastasis. *International Journal of Breast Cancer*, 2011, pp.1-6.
- Hinton, C., Avraham, S. and Avraham, H. (2010). Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. *Clinical & Experimental Metastasis*, 27(2), pp.97-105.
- Holland, J., Kochetkova, M., Akekawatchai, C., Dottore, M., Lopez, A. and McColl, S. (2006). Differential Functional Activation of Chemokine Receptor CXCR4 Is Mediated by G Proteins in Breast Cancer Cells. *Cancer Research*, 66(8), pp.4117-4124.
- James, J., Evans, A., Pinder, S., Gutteridge, E., Cheung, K., Chan, S. and Robertson, J. (2003). Bone metastases from breast carcinoma: histopathological – radiological correlations and prognostic features. *British Journal of Cancer*, 89(4), pp.660-665.
- Jin, and Mu, P. (2015). Targeting Breast Cancer Metastasis. *BCBCR*, p.23.

- Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P. and Starosławska, E. (2015). Breast cancer risk factors. *Menopausal Review*, 3, pp.196-202.
- Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M., Voduc, D., Speers, C., Nielsen, T. and Gelmon, K. (2010). Metastatic Behavior of Breast Cancer Subtypes. *Journal of Clinical Oncology*, 28(20), pp.3271-3277.
- Key, T., Verkasalo, P. and Banks, E. (2001). Epidemiology of breast cancer. *The Lancet Oncology*, 2(3), pp.133-140.
- Khuwaja, G. and Abu-Rezq, A. (2004). Bimodal breast cancer classification system. *Pattern Analysis and Applications*, 7(3), pp.235-242.
- Kim, J., Mori, T., Chen, S., Amersi, F., Martinez, S., Kuo, C., Turner, R., Ye, X., Bilchik, A., Morton, D. and Hoon, D. (2006). Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease Outcome. *Annals of Surgery*, 244(1), pp.113-120.
- Kroman, N., Jensen, M., Wohlfahrt, J., Mouridsen, H., Andersen, P., Melbye M. (2000). Factors influencing the effect of age on prognosis in breast cancer: Population based study. *BMJ*, 320, pp.474-478.
- Kucia, M., Reza, R., Miekus, K., Wanzeck, J., Wojakowski, W., Janowska-Wieczorek, A., Ratajczak, J. and Ratajczak, M. (2005). Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis. *Stem Cells*, 23(7), pp.879-894.
- Kufe, D., Pollock, R., Weichselbaum, R., Bast, R., Gansler, T., Holland, J. and Frei, E. editors. (2003). Holland-Frei Cancer Medicine. 6th edition. *Hamilton (ON): BC Decker*.
- Kumachev, A., Trudeau, M. and Chan, K. (2015). Associations among socioeconomic status, patterns of care, and outcomes in breast cancer patients in a universal health care system: Ontario's experience. *Cancer*, 122(6), pp.893-898.
- Kumar, V., Abbas, A. and Aster, J. (2015). Robbins and Cotran pathologic basis of disease. 1st ed. *Philadelphia: Elsevier-Saunders*.
- Li, C., Malone, K., Porter, P., Weiss, N., Tang, M., Cushing-Haugen, K. and Daling, J. (2003). Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer. *Obstetrical & Gynecological Survey*, 58(11), pp.733-735.
- Liang, Z., Yoon, Y., Votaw, J., Goodman, M., Williams L. and Shim H. (2005). Silencing of CXCR4 blocks breast cancer metastasis. *Cancer Res.*, 65, pp.967-971.
- Linton, P., Haynes, L., Tsui, L., Zhang, X., Swain, S. (1997). From naive to effector-alterations with aging. *Immunol Rev*, 160, pp.9-18.
- Lorusso, G. and Rüegg, C. (2012). New insights into the mechanisms of organ-

- specific breast cancer metastasis. *Seminars in Cancer Biology*, 22(3), pp.226-233.
- Makki (2015). Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, p.23.
- Marino, N., Woditschka, S., Reed, L., Nakayama, J., Mayer, M., Wetzel, M. and Steeg, P. (2013). Breast Cancer Metastasis: Issues for the personalization of its prevention and treatment. *The American Journal of Pathology*, 183(4), pp.1084-1095.
- McCarthy N. (2009). Metastasis: influencing bad behaviour. *Nat Rev Cancer*, 9, p.609.
- McGuire, A., Brown, J., Malone, C., McLaughlin, R. and Kerin, M. (2015). Effects of Age on the Detection and Management of Breast Cancer. *Cancers*, 7(2), pp.908-929.
- Miao, Z., Luker, K., Summers, B., Berahovich, R., Bhojani, M., Rehemtulla, A., Kleer, C., Essner, J., Nasevicius, A., Luker, G., Howard, M. and Schall, T. (2007). CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. *Proceedings of the National Academy of Sciences*, 104(40), pp.15735-15740.
- Mook, S., Schmidt, M., Rutgers, E., van de Velde, A., Visser, O., Rutgers, S., Armstrong, N., van't Veer, L. and Ravdin, P. (2009). Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. *The Lancet Oncology*, 10(11), pp.1070-1076.
- Mukherjee, D., and Zhao, J. (2013). The role of chemokine receptor CXCR4 in breast cancer metastasis. *American Journal of Cancer Research*, 3(1), pp.46–57.
- Murphy, P., Baggiolini, M., Charo, I., Hebert, C., Horuk, R., Matsushima, K., Miller, L., Oppenheim, J. and Power, C. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol. Rev.*, 52(1), pp.145–176.
- Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M., McClanahan, T., Murphy, E., Yuan, W., Wagner, S., Barrera, J., Mohar, A., Verástegui, E., and Zlotnik, A. (2001). Involvement of chemokine receptors in breast cancer metastasis. *Nature*, 410(6824), pp.50-6.
- Nyström, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjöld, B. and Rutqvist, L. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. *The Lancet*, 359(9310), pp.909-919.
- Okuyama Kishima, M., Oliveira, C., Banin-Hirata, B., Losi-Guembarovski, R., Brajão de Oliveira, K., Amarante, M. and Watanabe, M. (2015). Immunohistochemical Expression of CXCR4 on Breast Cancer and Its

Clinical Significance. *Analytical Cellular Pathology*, pp.1-6.

- Orel, S. (2005). 1–10 Efficacy of MRI and Mammography for Breast-Cancer Screening in Women With a Familial or Genetic Predisposition. *Breast Diseases: A Year Book Quarterly*, 16(1), pp.37-38.
- Patel, L., Camacho, D., Shiozawa, Y., Pienta, K. and Taichman, R. (2011). Mechanisms of cancer cell metastasis to the bone: a multistep process. *Future Oncology*, 7(11), pp.1285-1297.
- Phillips, R., Burdick, M., Lutz, M., Belperio, J., Keane, M. and Strieter, R. (2003). The Stromal Derived Factor–1/CXCL12–CXC Chemokine Receptor 4 Biological Axis in Non–Small Cell Lung Cancer Metastases. *American Journal of Respiratory and Critical Care Medicine*, 167(12), pp.1676-1686.
- Pulido, C., Vrendell, I., Ferreira, A., Casimiro, S., Mansinho, A., Alho, I. and Costa, L. (2017). Bone metastasis risk factors in breast cancer. *Ecancermedicalscience*, 11, p.715.
- Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P. and Starosławska, E. (2015). Breast cancer risk factors. *Menopausal Review*, 3, pp.196-202.
- Purushotham, A., Shamil, E., Cariati, M., Agbaje, O., Muhidin, A., Gillett, C., Mera, A., Sivanadiyan, K., Harries, M., Sullivan, R., Pinder, S., Garmo, H. and Holmberg, L. (2014). Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship. *European Journal of Cancer*, 50(10), pp.1697-1705.
- Pusat Data Dan Informasi Kementerian Kesehatan RI. (2015). Situasi Penyakit Kanker.
- Rakha, E., Reis-Filho, J., Baehner, F., Dabbs, D., Decker, T., Eusebi, V., Fox, S., Ichihara, S., Jacquemier, J., Lakhani, S., Palacios, J., Richardson, A., Schnitt, S., Schmitt, F., Tan, P., Tse, G., Badve, S. and Ellis, I. (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*, 12(4).
- Renshaw, A. (2011). Rosai and Ackerman Surgical Pathology Overview. *Advances In Anatomic Pathology*, 18(6), p.473.
- Rosai, J. (2011). 'Breast. In Rosai and Ackerman's Surgical Pathology'. 10th edition, *Philadelphia: Elsevier-Saunders*.
- Sacanna, E., Ibrahim, T., Gaudio, M., Mercatali, L., Scarpi, E., Zoli, W., Serra, P., Bravaccini, S., Ricci, R., Serra, L. and Amadori, D. (2011). The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study. *Oncology*, 80(3-4), pp.225-231.
- Salvucci, O., Bouchard, A., Baccarelli, A., Deschenes, J., Sauter, G., Simon, R., Bianchi, R. and Basik, M. (2006). The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. *Breast Cancer Research and Treatment*, 97(3), pp.275-283.
- Sarvaiya, P., Guo, D., Ulasov, I., Gabikian, P. and Lesniak, M. (2013).

- Chemokines in tumor progression and metastasis. *Oncotarget*, 4(12), pp.2171-2185.
- Shah, R., Rosso, K. and Nathanson, S. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology*, 5(3), pp.283-298.
- Sharma, G., Dave, R., Sanadya, J., Sharma, P. and Sharma, K. (2010). VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: AN OVERVIEW. *Journal of Advanced Pharmaceutical Technology & Research*, 1(2), pp.109-126.
- Shulman, L., Willett, W., Sievers, A. and Knaul, F. (2010). Breast Cancer in Developing Countries: Opportunities for Improved Survival. *Journal of Oncology*, pp.1-6.
- Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., Turpeenniemi-Hujanen, T., Isola, J., Heikkilä, P. and Joensuu, H. (2011). Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. *Breast Cancer Research*, 13(5), p.R87.
- Sinn, Hans, P. and Hans, K. (2013). A Brief Overview of the WHO Classification of Breast Tumors. 4th Edition. Focusing on Issues and Updates from the 3rd Edition. *Breast Care*, 8(2), pp.149–154.
- Stout, R. and Suttles, J. (2005). Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age associated microenvironmental changes. *Immunol Rev*, 205, pp.60-71.
- Strieter, R., Polverini, P., Kunkel, S., Arenberg, D., Burdick, M., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., Chan, S., Roczniak, S. and Shanafelt, A. (1995). The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis. *Journal of Biological Chemistry*, 270(45), pp.27348-27357.
- Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R., Pienta, K. and Wang, J. (2010). CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. *Cancer and Metastasis Reviews*, 29(4), pp.709-722.
- Sundquist, M., Thorstenson, S., Brudin, L. and Nordenskjöld, B. (1999). Applying the Nottingham Prognostic Index to a Swedish breast cancer population. *Breast Cancer Research and Treatment*, 53(1), pp.1-8.
- Teicher, B. (2011). Antiangiogenic agents and targets: A perspective. *Biochemical Pharmacology*, 81(1), pp.6-12.
- ten Haaf, A., Bektas, N., von Serenyi, S., Losen, I., Arweiler, E., Hartmann, A., Knüchel, R. and Dahl, E. (2009). Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. *BMC Cancer*, 9(1).
- Torre, L., Bray, F., Siegel, R., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015).

- Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians*, 65(2), pp.87-108.
- Warner, E., Messersmith, H., Causer, P., Eisen, A., Shumak, R. and Plewes, D. (2008). Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer. *Annals of Internal Medicine*, 148(9), p.671.
- Wong, D. and Korz, W. (2008). Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside. *Clinical Cancer Research*, 14(24), pp.7975-7980.
- World Health Organization. (2012). Global Health Estimates.
- Xu, C., Zhao, H., Chen, H., & Yao, Q. (2015). CXCR4 in breast cancer: oncogenic role and therapeutic targeting. *Drug Design, Development and Therapy*, 9, pp.4953–4964.
- Xu, T., Shen, H., Liu, L. and Shu, Y. (2013). The impact of chemokine receptor CXCR4 on breast cancer prognosis: A meta-analysis. *Cancer Epidemiology*, 37(5), pp.725-731.
- Youlten, D., Cramb, S., Dunn, N., Muller, J., Pyke, C. and Baade, P. (2012). The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. *Cancer Epidemiology*, 36(3), pp.237-248.
- Zagzag, D., Lukyanov, Y., Lan, L., Ali, M., Esencay, M., Mendez, O., Yee, H., Voura, E. and Newcomb, E. (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. *Laboratory Investigation*, 86(12), pp.1221-1232.
- Zlotnik, A. and Yoshie, O. (2000). Chemokines. *Immunity*, 12(2), pp.121-127.